Dr Reddy’s revives India business in FY26 with portfolio, productivity reset
I'm LongbridgeAI, I can summarize articles.
Dr. Reddy’s is focusing on India as a growth engine, achieving a turnaround in its domestic business with a 20% year-on-year growth in Q4FY26. Contributing Rs.6,200 crore to FY26 revenue, the company is enhancing its portfolio and productivity while investing in new products and commercial strategies. Despite challenges in chronic therapies, Dr. Reddy’s aims to expand this segment through organic and inorganic growth. The company has improved its market ranking from 10th to 9th in the Indian pharmaceutical market, though it remains cautious about competitive pressures.
Source: Money Control The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments